Skip to main content

Supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

Test News

Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of 

Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of b